Podcasts about clinical trials

FDA announces crackdown on misleading TV drug ads, influencers, online drug dispensaries; What's a “twisted colon”? Doctors often jump the gun in prescribing ADHD meds to young kids before behavioral fixes; A new era in skincare powered by urolithin A.

Let's say you or a family member wants to participate in a clinical trial, but the boss doesn't want you to have the time off because of extra visits to the doctor's office. Under new rules spearheaded by the Foundation for Sarcoidosis Research, companies must now allow patients time away from the job without fear of losing their employment.  In this special edition of the FSR Sarc Fighter Podcast, FSR CEO Mary McGowan joins me, along with Emily Dickens, Chief of Staff, Head of Government Affairs, and Corporate Secretary for Society for Human Resources Management.  Together they will walk us through the new guidelines for HR departments when it comes to allowing employees to participate in clinical trials.  @SHRM #SHRM #humanresources #clinicaltrial  Show Notes SHRM: https://www.shrm.org/ FSR News Release: https://www.stopsarcoidosis.org/coalition-to-transform-clinical-trial-engagement-launches-champions-for-change-pto-initiative/ More from FSR: https://www.stopsarcoidosis.org/fsr-receives-confirmation-from-the-department-of-labor-ensuring-patient-access-to-fmla-for-participation-in-clinical-trials/ MORE FROM JOHN: Cycling with Sarcoidosis http://carlinthecyclist.com/category/cycling-with-sarcoidosis/ Do you like the official song for the Sarc Fighter podcast?  It's also an FSR fundraiser! If you would like to donate in honor of Mark Steier and the song, Zombie, Here is a link to his KISS account.  (Kick In to Stop Sarcoidosis)  100-percent of the money goes to the Foundation.  https://stopsarcoidosis.rallybound.org/MarkSteier The Foundation for Sarcoidosis Research https://www.stopsarcoidosis.org/ Donate to my KISS (Kick In to Stop Sarcoidosis) fund for FSR  https://stopsarcoidosis.rallybound.org/JohnCarlinVsSarcoidosis?fbclid=IwAR1g2ap1i1NCp6bQOYEFwOELdNEeclFmmLLcQQOQX_Awub1oe9bcEjK9P1E My story on Television https://www.stopsarcoidosis.org/news-anchor-sarcoidosis/ email me  carlinagency@gmail.com #sarcoidosis #sarcoidosisawareness               

Ann Collins, PA, Blood Cancer United, Washington, DC, Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC, Sarah K. Tasian, MD, Children's Hospital of Philadelphia, Philadelphia, PA Recorded on September 9, 2025 Ann Collins, PA Project Leader, Pediatric Acute Leukemia Master Clinical Trial (PedAL) Blood Cancer United Washington, DC Kelly Laschinger, MSN, RN, […]

The 2024 Revisions of the McDonald Diagnostic Criteria for MS have been published in The Lancet Neurology. What do these changes mean for clinical practice? In this episode, we are joined by two authors of the paper: Prof. Xavier Montalban, Chair of the International Advisory Committee on Clinical Trials in MS (IACCTMS), and Dr. Jiwon Oh of the University of Toronto. Together with host Brett Drummond of MStranslate, they discuss the significance of the updates, how these changes could expedite diagnosis and reduce misdiagnosis, and what they mean for the future of MS care globally. Reference: Montalban, X. et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. https://doi.org/10.1016/S1474-4422(25)00270-4 (2025).

EP. 231:  On this episode we're digging into one of the most exciting frontiers in cellular medicine: how Urolithin A, a powerful compound, supports mitochondrial health and slows the effects of aging at the cellular level. If you've been feeling low energy, dealing with inflammation, or noticing your strength and resilience aren't what they used to be, this episode is packed with science-backed insights to help recharge your body from the inside out. My guest today is Dr. Brad Currier, PhD, Manager of Clinical Trials at Timeline, who's leading the way in Urolithin A research. We're talking muscle metabolism, brain health, immunity, and how this prebiotic compound could be a total game changer for longevity and overall vitality. → Head to timeline.com/DRTYNA to get started & Use code DRTYNA at checkout to receive 20% off today!  Topics Discussed: → What is Urolithin A and how does it help mitochondria? → How does Urolithin A support muscle and metabolism? → How are postbiotics, gut health, and GLP-1s connected? → What does Mitopure research show for immunity and brain health? → How can you use Timeline's Urolithin A daily? Sponsored By: →  Head to timeline.com/DRTYNA to get started & Use code DRTYNA at checkout to receive 20% off today!  On This Episode We Cover:  → 00:00:00 - Introduction  → 00:01:19 - Understanding Urolithin A  → 00:05:24 - Mitochondrial health  → 00:09:08 - Mitochondrial lifecycle  → 00:11:08 - Muscular growth & health  → 00:14:21 - Mitopure research  → 00:17:50 - Postbiotics & the gut microbiome  → 00:22:14 - GLP1s & the gut  → 00:26:31 - Gut rehabilitation  → 00:28:03 - Aging  → 00:31:26 - High protein diets & strength training  → 00:34:45 - Aging + muscle strength  → 00:39:34 - Mitopure, HRT, + stacking  → 00:46:21 - Skincare + topicals  → 00:49:25 - Immune health + inflammation → 00:52:37 - Summary  → 00:56:27 - Trying Timeline!  Show Links:  → Dr. Tyna's Strength Corner Further Listening:  → EP. 196 | The Answer Is The Gym | Quick + Dirty → Strength Training Playlist  Check Out Timeline →  Head to timeline.com/DRTYNA to get started & Use code DRTYNA at checkout to receive 20% off today!  Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.

Clinical research is critical to the development of life saving treatments. And ACCC has long supported equitable access to clinical trials, including efforts to ensure that these trials reflect the diversity of the populations they serve. ACCC has made the Just ASK™ Training Program and Site Self-Assessment available free-of-charge to help research sites address barriers to participation in cancer clinical trials among racial and ethnic populations. In this episode, CANCER BUZZ facilities a candid conversation with Glyniss Redman, who received treatment at Gibbs Cancer Center and Research Institute for multiple myeloma, and 2 members of her cancer treatment team: clinical research coordinator Audrianna Carrington and oncologist hematologist Dr. Tondre Buck, about overcoming barriers, ensuring shared decision-making, and improving the inclusion of historically underrepresented groups in clinical trials.   “If you look at cancers in general, treatments have gotten better over the years in almost every category, and we wouldn't be here if it wasn't for clinical trials.” – Tondre Buck, MD   “We're playing the long game here. Some of the information or this research may not be about me. This is about our future generation…so this is a legacy game for me…This is what I'm doing with my [one] wild and precious life. I want to be here as long as I possibly can, but I also want my offspring: my children, my grandchildren, and my great grandchildren to be here as well and [to] have a better experience as far as health care and cancer.” – Glyniss Redman   “We do have to talk about past unethical experimentation and research in order for us to better prepare how we're going to go forward…[transportation] is one barrier that we are tackling. You know, we don't want to put that stress on the patients who have to choose between gas, their physician visit, their food, or their medicine for the day. So that is a huge barrier, and you really want that population to be represented on the trial, because rural populations tend to have higher cancer rates.” – Audrianna Carrington   Tondre Buck, MD Oncologist Hematologist Gibbs Cancer Center and Research Institute Spartanburg, SC   Audrianna Carrington Clinical Research Coordinator Gibbs Cancer Center and Research Institute Spartanburg, SC   Glyniss Redman Poet and Patient with Multiple Myeloma   Resources:   The Just ASK™ Training Program, Site Self-Assessment, and Training Facilitation Guide   ACORI Call to Action Summit   Clinical Research Terms Glossary   Increasing Clinical Trial Accrual Through the Implementation of a Clinical Trials Navigator   Gibbs Cancer Center and Research Institute   Cancer Moonshot Biobank   National Estimates of the Participation of Patients With Cancer in Clinical Research Studies Based on Commission on Cancer Accreditation Data   TalkAboutTrials.com

More options, more questions. Get clarity on patient selection and optimizing adjuvant cyclin-dependent kinase cyclin-dependent kinase (CDK)4/6 inhibitor therapy. Credit available for this activity expires: 9/16/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002908?ecd=bdc_podcast_libsyn_mscpedu

In this episode of Conversations in Lung Cancer Research, host A/Prof Mel Moore interviews Prof Anna Nowak, a renowned medical oncologist, clinical trialist, and tumour immunology researcher. We learn of Anna's early aspirations influenced by her family and mentors, her educational and professional trajectory, and her transition to a leadership role as Deputy Vice Chancellor at the University of Western Australia. Anna shares insights on the challenges and rewards of juggling clinical practice with research, her contributions to mesothelioma studies, involvement in the DREAM and DREAMER trials, and her role in mentoring the next generation of oncologists.(00:00) Welcome and Acknowledgements(00:34) Introducing Professor Anna Nowak(01:50) Anna's Journey into Medicine(03:18) Transition to Oncology and Research(05:05) PhD and Early Research Experiences(09:15) Clinical Trials and Mesothelioma Focus(24:58) Leadership and Academic Roles(31:48) Mentorship and Future Aspirations(32:39) Conclusion and Farewell

You're living with MS, and maybe you're thinking about participating in an MS clinical trial. But how do they work? Are they safe? What's the difference between Phase 1, 2, and 3 trials? What are the real patient risks and benefits of participating in a clinical trial? In this special episode of RealTalk MS, we're getting answers to those questions and so much more from my guest, Dr. Aaron Boster. Dr. Boster is the founder of the Boster Center for Multiple Sclerosis in Columbus, Ohio, where he brings over 20 years of experience as an MS clinician. Dr. Boster has also  participated in more than 65 clinical trials.  This special episode of RealTalk MS has been made possible through a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct1 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy

In the Season 6 premiere of the Wealth Planning for the Modern Physician Podcast, host David Mandell welcomes Dr. Cynthia Matossian, an accomplished ophthalmologist, entrepreneur, and industry leader. Dr. Matossian shares her unique journey into medicine, starting from an initial interest in political science and international relations before ultimately discovering her passion for ophthalmology. She discusses the early challenges she faced in starting her own practice in 1987, particularly as a woman seeking financial backing in a male-dominated field, and the resilience and determination that fueled her success. Dr. Matossian reflects on the growth of her solo practice into a thriving multi-location enterprise with 14 physicians and over 90 employees. She emphasizes the importance of delegation, transparency, and staff empowerment in building an efficient, patient-focused practice. Her insights into practice management include implementing scribes to reduce physician burnout, investing in proper business education, and hiring skilled managers to bring structure and professionalism to the organization. She also highlights her personal approach to financial planning, beginning with small investments guided by a trusted advisor, which laid the foundation for long-term financial success. The conversation also explores Dr. Matossian's involvement in industry innovation, her leadership in clinical trials, and her founding of GPOptho, a group purchasing organization designed to help practices lower costs through collective buying power. She shares valuable advice for physicians considering private equity transactions, stressing the importance of preparing years in advance and selecting the right advisors. Ultimately, Dr. Matossian underscores the critical need for physicians to educate themselves on the business of medicine early in their careers, pairing clinical excellence with sound financial and practice management strategies. Learn more, including additional show notes, links, and detailed key takeaways, by visiting physicianswealthpodcast.com. Click here to get your FREE copy of our latest book, Wealth Strategies for Today's Physician!

Send us a textDr. Michael Myers joins Dr. Michael Koren for an interview about his physician journey from medical school to private practice, healthcare administration, health consulting, teaching, and writing. Dr. Myers talks about his serendipitous journey through many parts of the healthcare system and how this shaped his unique career path through medicine's changing landscape. The two also transition to modern discussions on vaccines and the need for credible information in this space.Dr. Myers is writing a book titled "The Vaccine Bible," to be published on Amazon: https://www.amazon.com/stores/author/B0BL15KXRV/allbooksBe a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Hoffman continues his conversation with Martha Carlin, CEO and founder of the Bio Collective.

Martha Carlin, CEO and founder of the Bio Collective, details the significant influence of the microbiome on overall health. Martha discusses her unconventional path from accounting to microbiome research, sparked by her husband's Parkinson's diagnosis. Together, they explore the complex connections between gut health and diseases like Parkinson's, autism, and even Alzheimer's. Martha sheds light on groundbreaking research funded by NIH grants, the potential of machine learning and AI in understanding microbiome patterns, and the future prospects of personalized probiotics. Practical advice on maintaining a healthy microbiome, the impact of diet and exercise, and the intriguing intersections between gut health, neurochemistry, and systemic diseases are highlighted. The discussion also covers challenges in integrating microbiome research into clinical practice and potential future therapies.

Dr Emma Law, narrating her blog written for the Dementia Researcher website. Recruiting participants for clinical trials is one of the toughest barriers in research, particularly in dementia studies where strict inclusion criteria apply. In this guest blog, Dr Emma Law shares her experience on why recruitment is so difficult, the funnel effect of screening, and the limitations of existing tools. She also highlights strategies that work best, including NHS memory clinics, permission-to-contact schemes, and new developments such as the NHS App. Her reflections reveal the challenges and opportunities that can make a difference in speeding up research and treatment access.   Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-recruiting-participants-for-clinical-trials/ #DementiaResearch #ClinicalTrials #Research #TrialDelivery -- Dr Emma Law is Strategic Manager for the The Neuroprogressive and Dementia Network in Scotland. Emma has 13 years experience as a Clinical Trails Network Manager and over 35 years experience as a Nurse, many of which were spent in the delivery of Clinical Research Trials. Emma completed her PhD and is passionate about giving people living with dementia and their carers access to participate in research.  --   Enjoy listening? We're always looking for new bloggers, drop us a line. http://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Join our community: https://onelink.to/dementiaresearcher

Dr. Bradley Ong discusses the efficacy and safety of fremanezumab in adults with migraine and comorbid major depressive disorder. Show reference: https://jamanetwork.com/journals/jamaneurology/fullarticle/2833452 

Alternatives to surgery for venous insufficiency; AI “hallucinates” a never-before-seen brain region in crucial test; Vegetarian complains she is prone to falling; Could tinnitus be triggered by electromagnetic fields from lighting, devices? Cannabis derivatives improve sleep where drugs fail; A novel way of treating chronic nasal infections—with snot transplants! Mitochondrial dysfunction found to be the key to heart, brain problems.

In this podcast, experts Filipa Lynce, MD, and Rita Nanda, MD, discuss recent clinical trial and real-world data for antibody-drug conjugates (ADCs) used to treat triple-negative breast cancer (TNBC).

With Børge Nordestgaard and Anders Berg Wulff, Copenhagen University Hospital, Copenhagen - Denmark. Read the European Heart Journal - Cardiovascular Imaging paper Read the European Heart Journal - Cardiovascular Imaging editorial

NACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.

Support the show and get 50% off MCT oil with free shipping—just leave us a review on iTunes and let us know!https://podcasts.apple.com/us/podcast/live-beyond-the-norms/id1714886566 A medical doctor gets an incurable diagnosis, lands in a wheelchair, and is told there's no hope. Instead of accepting her fate, she created a protocol that not only stopped her disease but reversed it.In this episode, I sit down with the incredible Dr. Terry Wahls, who shares her stunning story of going from being unable to sit up on her own to walking, biking, and jogging again. Dr. Wahls explains how she used functional medicine and a deep understanding of mitochondrial health to reclaim her life from progressive Multiple Sclerosis. She reveals the specific diet, exercise, and electrical stimulation methods that were central to her recovery."I was happy to die today to avoid being disabled tomorrow." ~ Dr. Terry WahlsMentioned in the Episode:Dr. Wahls' Clinical Trials: https://terrywahls.com/trials About Dr. Terry Wahls:Dr. Terry Wahls is a clinical professor of medicine at the University of Iowa, where she conducts clinical trials. She is also a patient with secondary progressive multiple sclerosis, which confined her to a tilt-recline wheelchair for four years. Dr. Wahls restored her health using a diet and lifestyle program she designed specifically for her brain and now pedals her bike to work. She is the author of The Wahls Protocol: A Radical New Way to Treat All Chronic Autoimmune Conditions Using Paleo Principles, and the cookbook, The Wahls Protocol Cooking for Life.Connect with Dr. Terry Wahls:- Website: https://terrywahls.com/ - Instagram: https://www.instagram.com/drterrywahls/ - Facebook: https://www.facebook.com/TerryWahls/ - YouTube: https://www.youtube.com/c/TerryWahlsMD Connect with Chris Burres:- Website: https://www.myvitalc.com/ - Website: http://www.livebeyondthenorms.com/ - Instagram: https://www.instagram.com/chrisburres/ - TikTok: https://www.tiktok.com/@myvitalc - LinkedIn: https://www.linkedin.com/in/chrisburres/ 

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this interview, we sit down with John Tobin, Vice President of Clinical Operations at Splice Bio, to explore groundbreaking gene therapy research for Stargardt's disease and its potential impact on the blind and visually impaired community. John shares insights into Splice Bio's mission, how their innovative work could transform options for people living with vision loss, and what families, professionals, and supporters should know about emerging treatments. Stay tuned until the end for information on how to get involved in Splice Bio's clinical trials. Learn more here: www.splice.bio/clinical Or send an email to: Clinicaltrials@splice.bio #SpliceBio #genetherapy #clinicaltrials

Delays in diagnosing and treating pulmonary hypertension (PH) can have life-altering consequences. In this episode, Dr. Kari Gillmeyer, discusses her groundbreaking study on PH care networks. She explores why so many patients experience delays, how geography and provider access play a role, and what can be done to improve timeliness of care. This Special Edition Episode Sponsored by: Johnson & Johnson Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @VABostonHC @The_BMC @JNJInnovMed

As clinical research becomes increasingly digital, the legal and compliance landscape is shifting. Hal Porter, Director of Consulting Services, Clearwater, speaks with Dianne Bourque, Partner, Holland & Knight LLP, about the legal, regulatory, and ethical considerations when clinical trial data is compromised. They discuss issues related to regulatory frameworks and legal obligations, risk exposure and liability, impacts of a breach that go beyond privacy, cross border data and transfer risks, and mitigating the risk and fallout of data breaches in clinical trials. Sponsored by Clearwater.Watch this episode: https://youtu.be/XwtZXXGmLx4Learn more about Clearwater: https://clearwatersecurity.com/ Essential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation. 00:00 Introduction and Guest Welcome00:25 Christian Rommel's Journey in Oncology03:02 The Importance of Collaboration in Innovation05:16 Balancing Risk and Reward in Drug Development18:07 The Role of AI and Data in Modern R&D22:33 Partnerships and External Learning26:16 Balancing Legacy and Innovation in Biotech27:18 Global Expansion and Leadership Diversity27:27 Courage in Biotech Management27:54 Inspiration from Roche Genentech30:26 Commitment to Product Supply and Market Readiness32:23 Challenges of Global Launches35:53 Emerging Trends in Pharma: AI and Genetic Medicines42:20 Decision-Making in Pharma47:30 Reflections on Academic and Professional Journey Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Christian Rommel;LinkedIn: https://www.linkedin.com/in/christian-rommel/Website: https://www.bayer.com/en/innovation/science-research-and-innovation Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

The University of Galway is leading three new projects that aim to make medical treatments safer, faster and more effective after researchers secured the support of one of Europe's most prestigious funding programmes. The awards were made by the European Commission's Marie Sklodowska Curie Actions-Doctoral Network programme (MSCA DN), as part of Horizon Europe 2020. The programme supports researchers to become future leaders while investing in the University of Galway projects to improve lives and pave the way for better, more affordable healthcare. The network also provides training to make the researchers more creative, entrepreneurial and innovative, boosting their employability in the long term. One University of Galway project has an emphasis on sustainability and a move away from animal testing for brain disease; a second is looking at cardiovascular issues, specifically around improving heart stent durability and longevity; and a third seeks to advance equity, diversity and inclusion in clinical trials. Professor Fidelma Dunne, Director of the Institute for Clinical Trials at the University of Galway, said: "These projects show how research can make a real difference in people's lives. University of Galway is proud to be leading the way in creating smarter, safer, and more sustainable healthcare solutions." Professor Ted Vaughan, Interim Director of the Institute for Health Discovery and Innovation at the University of Galway, said: "These projects exemplify the mission of our new Institute - to accelerate fundamental and applied understanding of disease and enable disruptive solutions to health-based challenges. By combining cutting-edge science with collaborative training, we are not only advancing medical technologies but also shaping the next generation of research leaders. This investment from the European Commission underscores the importance of innovation that is ethical, inclusive, and focused on improving patient outcomes across society." The University of Galway projects funded by the Marie Sklodowska Curie Actions-Doctoral Network are: Dr Mihai Lomora leads the €4.2 million CerebroMachinesTrain Doctoral Network research project - Smarter Drug Delivery for Brain Diseases. Using advanced 3D brain models that mimic real brain tissue, the project will test tiny machines which are being developed to bring medicine exactly where it is needed. It avoids animal testing, making research faster, more ethical, and more accurate. Dr Lomora is a Lecturer and Principal Investigator in Bio(material) Chemistry at the University's School of Biological and Chemical Sciences in the College of Science and Engineering and a Funded Investigator at CÚRAM - the Research Ireland Centre for Medical Devices. This network project involves 14 partners from eight countries, including the US. Four PhD students will be supported through the project at the University of Galway. Dr William Ronan leads the €2.71 million MEDALLOY research project - Stronger, Safer Materials for Life-Saving Devices. It focuses on making materials used in minimally invasive medical devices - like stents and heart valve supports - stronger and longer lasting. Dr Ronan is a Lecturer and Principal Investigator in Biomedical Engineering at the University's College of Science and Engineering. The project includes partners from six countries - the US, Ireland, Italy, Germany, Czechia and Sweden. It will train nine PhD students, who will spend at least half of their time working directly in industry, earning hands-on skills ranging from material science to patient care. Dr Eimear Morrissey leads the €4.4 million EDICT research project - Advancing Equity, Diversity and Inclusion in Clinical Trials. It is a research and training network led by the Health Research Board-Trials Methodology Research Network, based at the University of Galway, which seeks to include older adults, ethnic minorities, people with disabilities, or those from lower-income backgrounds in clinica...

Health care executive Shelli Pavone discusses her article "Why retail pharmacies are the future of diverse clinical trials," highlighting the urgent need to improve representation in clinical research. Shelli explains how barriers like mistrust, cost, and lack of access have historically excluded women and minority populations, leading to less effective treatments and persistent health disparities. She describes how leveraging retail pharmacies—trusted, accessible community hubs—can decentralize trials, expand recruitment, and boost retention. Listeners will gain practical insights on how pharmacies' existing infrastructure can be adapted for clinical research, why inclusivity matters for health outcomes, and how patient-centered innovation can reshape the future of medicine. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Carole Bakhos joins us for an update on where we stand with the clinical trial. There are a few spots open now so take a listen to see if you are eligible to get involved. A must listen for all of our families!

Send us a textDr. Michael Koren joins Kevin Geddings to discuss the importance of taking reasonable precautions for health and safety. He recounts his experience at a recent Jacksonville Jaguars football game, which was delayed out of an abundance of caution due to a lightning storm. Dr. Koren explains that although the delay was annoying and disruptive, safety must come first. The two relate this to health-related precautions, such as managing cholesterol and obesity, as well as the rigorous safety measures in clinical trials.   Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Tolaney focuses on advancing breast cancer treatment through innovative clinical research. She has been instrumental in developing novel therapies and leading key clinical trials, particularly for early-stage HER2-positive breast cancer.     Timestamps   00:09 – Introduction  01:12 – What is HER2-positive breast cancer?  03:00 – Key trials Tolaney has led  07:16 – Antibody-drug conjugates  12:00 - Breast Oncology Guidelines  14:51 – Treatment optimisation   18:27 – Equity in healthcare  21:10 – Mentoring the next generation of oncologists  22:52 – Tolaney's wishes for healthcare 

Nutritionist Leyla Muedin discusses recent advancements in the detection and prevention of Alzheimer's disease. Topics include the new FDA-approved Lumipulse blood test, the role of a ketogenic diet in improving mitochondrial health, and the significance of lifestyle changes such as social and cognitive activities. The episode also highlights promising research from the University of California Irvine on using natural compounds like nicotinamide and EGCG to rejuvenate aging brain cells and address the buildup of Alzheimer's-associated proteins. Leyla also provides insights into the difference between Alzheimer's and general dementia and emphasizes the importance of accurate diagnosis and appropriate treatments.

To subscribe to our podcast and YouTube channel visit: https://www.youtube.com/@davisphinneyfdn/podcasts More people with Parkinson's are impacted by the LRRK2 (often pronounced "Lark two") gene than you might expect. The NEULARK study is a phase II clinical trial designed to investigate whether a new treatment being researched, NEU-411, can slow disease progression and improve quality of life for people with Parkinson's disease. NEU-411 is an oral medication designed to inhibit overactivity of the LRRK2 gene. In this episode of The Parkinson's Podcast, we talk with Dr. Fatta Nahab about the NEULARK study. This episode is sponsored by Neuron23, who is also sponsoring the NEULARK study. Our guest, Dr. Nahab, is Vice President of Clinical and Digital Development for Neuron23.  For more information about the NEULARK trial please visit:  https://parkinsonsresearchlrrk2.com/  or  https://clinicaltrials.gov/study/NCT06680830   Season: 6 Episode: 19

In today's episode, we passed the mic to Tara E. Seery, MD, who moderated an OncLive Insights discussion on the future of the pancreatic cancer treatment paradigm. Rounding out the discussion with additional expert perspectives were Paul E. Oberstein, MD, and Priyadarshini Pathak, MBBS. Seery is a medical oncologist at the Hoag Family Cancer Institute in Newport Beach, California. Oberstein is an associate professor in the Department of Medicine at the New York University (NYU) Grossman School of Medicine; as well as the director of the Gastrointestinal Medical Oncology Program, the assistant director of the Pancreatic Cancer Center, and the service chief of the Gastrointestinal Medical Oncology Program at NYU Langone's Perlmutter Cancer Center. Pathak is an assistant in medicine at Massachusetts General Hospital and an instructor in medicine at Harvard Medical School in Boston.  In this exclusive conversation, Drs Seery, Oberstein, and Pathak highlighted key data from the phase 3 NAPOLI 3 trial (NCT04083235) of NALIRIFOX (liposomal irinotecan, 5-fluorouracil [5-FU], leucovorin, and oxaliplatin) vs nab-paclitaxel (Abraxane) and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma; the toxicity profiles of NALIRIFOX and FOLFIRINOX (leucovorin, 5-FU, irinotecan, and oxaliplatin); real-world data with these regimens, and more. 

Psychedelics like LSD, psilocybin, and ketamine are being tested to treat disorders like PTSD and anxiety.

In this episode of Longevity by Design, Dr. Gil Blander welcomes Dr. Eric Verdin, President and CEO of the Buck Institute for Research on Aging. Eric discusses the science behind therapeutic plasma exchange (TPE) and its potential to slow biological aging in humans. The conversation explores findings from a recent clinical trial, including measurable age reversal using epigenetic clocks.Eric explains how removing and replacing plasma can dilute pro-aging factors in the blood, a concept inspired by earlier animal studies on parabiosis. He also describes why rigorous, placebo-controlled human trials are crucial for validating longevity interventions and distinguishing the field from hype-driven wellness trends.The episode also highlights how omics data, such as metabolomics and proteomics, are shaping a new era of precision aging research. Eric emphasizes the value of lifestyle interventions as a foundation and sees future opportunities in combining TPE with personalized strategies to extend healthspan.  Guest-at-a-Glance

Inato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

Meet Sarah Kennedy, CEO and founder of Calocurb, a revolutionary weight management product born from 15 years and $30 million of New Zealand government-backed science. If you've ever struggled with your relationship to food, including overeating, yo-yo dieting, or the constant battle with your willpower, this conversation will give you a refreshing new perspective.We explore the fascinating science of appetite suppression, from the evolutionary role of hunger and the “hindbrain” to the discovery that bitter compounds in hops can naturally stimulate GLP-1 and other satiety hormones. We also get into the history of how Scottish highlanders and Kalahari tribes used bitter plants for appetite control, how modern agriculture stripped bitters from our diet, and why restoring this missing piece could be a game-changer. If you've been looking for a natural, science-backed way to modernize your eating habits and find peace with food, this episode is for you. Visit calocurb.com/lukestorey and use code LUKE10 for 10% off your first order.DISCLAIMER: This podcast is for educational purposes only and not intended for diagnosing or treating illnesses. The hosts disclaim responsibility for any adverse effects from using the information presented. Consult your healthcare provider before using referenced products. This podcast may include paid endorsements.THIS SHOW IS BROUGHT TO YOU BY:KORRECT | Go to korrectlife.com/luke and use the code LUKE to get 15% off.FLFE | Try Focused Life-Force Energy for FREE for 15 days at lukestorey.com/flfe.SUNLIGHTEN | Save up to $600 when you go to lukestorey.com/sunlighten and use code LUKESTOREY in the pricing form.JUST THRIVE | Head to lukestorey.com/justthrive and use code LUKE20 to save 20%.MORE ABOUT THIS EPISODE:(00:00:00) The Science Behind Appetite Suppression(00:21:45) Clinical Trials, Hunger Science, & Alternatives to Injectables(00:38:37) Bitters, Dosing Protocols, & What's Actually in Calocurb(00:57:27) GLP-1 Side Effects, Vagus Nerve, & Fasting Use Cases(01:09:34) Sarah's Journey, Innovation, & Life LessonsResources:• Website: calocurb.com • Instagram: instagram.com/calocurb • Facebook: facebook.com/calocurbGLOBAL • X: x.com/Calocurb • TikTok: tiktok.com/@calocurb • YouTube: youtube.com/@calocurb • Shop all our merch designs at lukestoreymerch.com• Check out Gilded By Luke Storey:

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textDr. Michael Koren joins Kevin Geddings to report live from Madrid on new developments being presented at the European Society of Cardiology meeting. This medical gathering, now the world's largest, is a showcase of developments in heart health and medicine. Dr. Koren notes excitement about progress in treating a genetic condition, lipoprotein(a), which raises cholesterol independently from diet and exercise. He notes that progress in this field is showing promise and that those with a family history of heart disease should have their lipoprotein(a) checked!Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Living with MS means living with uncertainty, possible physical disability or cognitive dysfunction, bouts of crushing fatigue, mood changes, and let's not forget the very real irritation of well-meaning people telling you how healthy you look. Just processing the world around you can feel challenging. In this episode, psychologist Dr. Miriam Franco joins me to discuss how developing a growth mindset can make all the difference in how you experience your MS journey.   We're also sharing a real-world example of how the drastic cuts in federal funding are already impacting MS care. We'll tell you about the first country in the world to approve Tolebrutinib, a new disease-modifying therapy for nonrelapsing secondary progressive MS. And we'll explain why people are particularly excited about this medication. We'll share details about the MS Clinical Imaging and Data Resource that's been launched by the International Progressive MS Alliance. We'll tell you how and where to catch the MS Standup Comedy Benefit next Monday in New York. And we're reminding you about your opportunity to impact future MS therapies by helping the FDA better understand what living with MS is really like. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Developing a growth mindset  :22 How those federal research funding cuts are impacting MS patient care  1:30 United Arab Emirates becomes the first country in the world to approve Tolebrutinib for nonrelapsing secondary progressive MS  5:05 The International Progressive MS Alliance launches an MS Clinical Imaging and Data Resource open to the MS research community   8:32 The MS Standup Comedy Benefit takes place next Monday in New York  10:15 Add your voice and participate in the Shaping Tomorrow Together initiative  11:04 Dr. Miriam Franco discusses what it means to have a growth mindset when you're living with MS   14:50 Share this episode  34:11 Next week's episode   34:31 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/418 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 VIDEO: Dr. Robert Fox, Principal Investigator in the Phase 3 Clinical Trial for Tolebrutinib and Secondary Progressive MS https://youtu.be/tJQ93qdlXrU?si=S5jREy5ixVcE7ol- VIDEO: Dr. Jiwon Oh, Principal Investigator in the Phase 3 Clinical Trial for Tolebrutinib and Relapsing-Remitting MS https://youtu.be/zcBmAHRTotA?si=n86KRjB9Xt9sdZMg The International Progressive MS Alliance Clinical Imaging and Data Resource https://progressivemsalliance.org/ms-clinical-and-imaging-data-resource ATTEND: MS Stand-Up Comedy Benefit  https://msstandup.org Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 418 Guest: Dr. Miriam Franco Privacy Policy

Join us as we delve into the evolving landscape of clinical trials in Latin America with Julio G. Martinez-Clark, CEO of BioAccess. Discover how his company is pioneering pathways for medtech innovators and shaping the future of medical device innovation in emerging markets.   Bioaccess® is a trailblazing company that's helped over 100 Medtech innovators navigate global clinical trials, and he currently serves as Ambassador of International Accrediting Organization for Clinical Research in the Americas. With a career that spans healthcare infrastructure, telecommunications, and regulatory strategy, Julio is a leading voice in the field of medical device innovation in emerging markets.   From his early days at Johns Hopkins Hospital to his current role in shaping ethical and efficient trial systems across Latin America, Julio's mission is clear: to expand access to high-quality research for patients and sponsors alike. He's also the host of the Global Trial Accelerators™ podcast, where he dives into trends in Medtech, Biopharma, Radiopharma and clinical trial innovation.   We unpack what makes Latin America a strategic region for clinical trials, especially for rare diseases, and explore how improving trial access can speed innovation, and change lives.   Episode Discussion Topics:    Introduction to Julio G. Martinez-Clark and his role at BioAccess. The clinical trial landscape in Latin America and its strategic importance. Julio's career journey from Johns Hopkins Hospital to BioAccess. The impact of cultural competence and community engagement on clinical trials. Challenges and solutions for conducting clinical trials during the pandemic. The role of artificial intelligence and digital tools in clinical trials. The future of clinical research in Latin America, including radiopharmaceuticals and theranostics. The importance of international standards and certifications for clinical research sites. Success stories and innovative approaches in clinical trials. Julio's podcast, Global Trial Innovators, and its focus on industry education. During the episode a blog post on bioaccess' website was referenced that highlights academic papers that talk about the higher recruitment and retention rates in Latin America, here it is: https://www.bioaccessla.com/blog/the-latin-american-advantage-why-clinical-trial-recruitment-and-retention-outpace-the-us-and-europe   Connect With Us:   Stay tuned for the next new episode of “It Happened To Me”! In the meantime, you can listen to our previous episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “It Happened To Me”.    “It Happened To Me” is created and hosted by Cathy Gildenhorn and Beth Glassman. DNA Today's Kira Dineen is our executive producer and marketing lead. Amanda Andreoli is our associate producer. Ashlyn Enokian is our graphic designer.   See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, ItHappenedToMePod.com. Questions/inquiries can be sent to ItHappenedToMePod@gmail.com. 

Send us a textIn this episode of the Life Science Success Podcast my guest is Victoria Donovan. Victoria is the Founder and CEO of Clinically Media, an award-winning agency that is transforming patient recruitment and retention strategies in clinical research.00:00 Introduction to Life Science Success Podcast00:38 Meet Victoria Donovan: Founder and CEO of Clinically Media01:34 Victoria's Journey into Life Sciences03:12 The Birth and Growth of Clinically Media05:03 Clinically Media's Mission and Vision08:46 Innovative Approaches in Patient Recruitment11:59 Challenges and Future of Patient Recruitment23:45 Leadership and Personal Insights from Victoria Donovan32:34 Conclusion and Final Thoughts

Dean's Chat hosts, Drs. Jensen and Richey, welcome Dr. Laura Brinker to the podcast! Laura Brinker, DPM, was previously a Vice President of Clinical Affairs at Paragon 28, where she drove innovation in foot and ankle surgical solutions. She now has a consulting firm to address advancements of medical devices, regulatory compliance, and clinical trials. With a background in Mechanical Engineering from Purdue and a DPM from Temple University, she completed her residency at the University of Louisville/Jewish Hospital. Dr. Brinker has combined private practice experience, clinical research, and engineering expertise to advance podiatric surgery and medical device development. Enjoy this entrepreneurial discussion with a young leader in our profession!

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:  Introduction (0:00) A Farmer with Myeloma; Is Myeloma the New Chronic Myeloid Leukemia? (2:06) Clinical Trials (12:34) Chimeric Antigen Receptor Therapy (16:11) Bispecific Antibodies (21:38) Antibody-Drug Conjugates; a Patient on Belantamab Mafodotin for 3 Years (30:45) Treatment Options for Relapsed Disease (40:46) Neuropathy (44:43) Alternative Therapies (48:36) 164 Questions (53:20) CME information and select publications

Dr. Hoffman continues his conversation with Stephen T. Talcott, Ph.D., Professor of Food Chemistry, Department of Food Science and Technology at Texas A&M University, about the powerful health benefits of the muscadine grape.

In this episode of the Intelligent Medicine podcast, Dr. Ronald Hoffman discusses the health benefits of Muscadine grapes with Dr. Stephen Talcott, a PhD chemist and professor of Food Chemistry at Texas A&M. The conversation delves into the unique biochemical properties of Muscadine grapes, their polyphenol content, and their potential health benefits compared to other fruits like Acai and common grapes. They also explore the bioavailability of nutrients, the role of phytoalexins, and the benefits of Muscadine grape-derived products. Dr. Talcott shares his insights on ongoing research at Wake Forest University, the advantages of Muscadine grape products for chemotherapy patients, and the benefits of using these products as natural health supplements. The episode highlights various Muscadine grape products available from Mighty Muscadine and Vinetastic, including juices, supplements, and topical applications, and offers a special discount code for listeners.

The deficits from the lead poisoning continue to intensify, Shannon channels her anger and grief into holding the people who hurt her son responsible.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.EP4 features Eboni Booth, Sasha Eden, Kevin Kane, April Matthis, Alysia Reiner, and Mandy Siegfried. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

View the Show Notes For This Episode Dr. Andrea McBeth discusses how Stool-derived Postbiotics can restore gut health with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.]   Podcast Highlights   In this episode of the Rational Wellness Podcast, host Dr. Ben White discusses postbiotics with Dr. Andrea McBeth, a naturopathic clinician and expert in functional gastroenterology and the microbiome. Dr. McBeth shares insights into her work with fecal microbial transplants and her development of the pheno-biotic supplement made from sterilized fecal matter. The conversation dives into the benefits of postbiotics for various gastrointestinal conditions and overall gut health, the complexities of bile acids and their roles in the body, and the emerging understanding of the microbiome's impact on brain and immune function. Dr. McBeth also highlights the stringent criteria for selecting stool donors for her supplements and announces an innovative partnership for clinical trials to gather more data on the effectiveness of postbiotics.     00:29 Meet Dr. Andrea Macbeth: Expert in Functional Gastroenterology 01:26 The Science and Benefits of Fecal Microbial Transplants 04:50 Exploring Bile Acids and Their Clinical Importance 10:02 Understanding Prebiotics, Probiotics, and Postbiotics 12:28 The Development and Benefits of Sterilized Postbiotic Products 14:36 The Apollo Wearable: Managing Stress and Improving Sleep 16:07 How Postbiotics Enhance Gut Health and Overall Wellbeing 28:01 The Role of the Microbiome in Immune Education 29:02 Postbiotics and Their Complementary Role 31:51 Clinical Trials and Data Collection 32:58 Dosage Recommendations and Usage 35:52 Probiotics vs. Fecal Microbiota Transplantation (FMT) 42:20 Misconceptions About the Gut Microbiome 48:19 Sourcing and Criteria for Donor Stool 50:04 Conclusion and Final Thoughts       ___________________________________________________________________ Dr. Andrea McBeth is the founder and CEO of Thaena, a pioneering microbiome therapeutics company. She has a Bachelor's in Biochemistry, focusing on molecular biology, and a Doctorate in Naturopathic Medicine. Early in her career, Andrea directed her ND clinical practice toward functional GI disorders and autoimmunity, launching one of the first stool banks for fecal microbiota transplantation to treat Clostridioides difficile infections.  Driven by the interface between gut microbes and human health, Andrea invented ThaenaBiotic, the first human-derived postbiotic supplement. The website is Thaena.com. Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure.  Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.